

The Role of Cytokines in COVID-19

December 1, 2020

9:00am - 3:00pm ET

via [Vbrick](#)

Introduction - 9:00am

Amy Rosenberg, *FDA*

Anthony S. Fauci, *NIAID*

Janet Woodcock, *FDA*

Session 1 - 9:20am

Cellular origins of cytokine responses in COVID-19

- **9.20am Adrian Hayday**, *King's College London*: Managing the threat of COVID-19 disease via immunological insights
- **9.40am Nina Le Bert**, *Duke-NUS Medical School*: Virus-specific cellular immunity in asymptomatic SARS-CoV-2 infection
- **10.00am Raphaela Goldbach-Mansky**, *NIAID*: Inflammatory Mediators in COVID: from gathering storm to tempest...
- **10.20am Alessandro Sette**, *La Jolla Institute for Immunology*: The role of adaptive immunity in SARS CoV2 infection and COVID disease
- **10.40am Q&A Moderator: Howard Young**, *NCI*

Session 2 - 11:20am

Multisystem Inflammatory Disorder in Children association with COVID-19

- **11.20am Randy Cron**, *University of Alabama*: Who Would Have Predicted MIS-C?
- **11.40am Dusan Bogunovic**, *Icahn School of Medicine at Mount Sinai*: Systems Immunology in MIS-C
- **12.00pm Carrie Lucas**, *Yale School of Medicine*: Toward defining immunopathology mechanisms in MIS-C
- **12.20pm Q&A Moderator: Aleksandra Nita-Lazar**, *NIAID*

Session 3 - 1:00pm

Autoimmunity and other long-term consequences of COVID-19

- **1.00pm Alessio Fasano**, *Massachusetts General Hospital*: COVID-19 and autoimmunity co-morbidity: Who is the chicken and who is the egg?
- **1.20pm Virginia Pascual**, *Cornell University*: TBA
- **1.40pm Leonard Calabrese**, *Cleveland Clinic*: The intersection of COVID19 and autoimmunity/autoinflammatory diseases: bi-directional clinical consequences
- **2.00pm Q&A Moderator: Daniela Verthelyi**, *FDA*

Conclusion - 2:30pm

Howard Young, *NCI*

For more information, contact:

Amy Rosenberg, Amy.Rosenberg@fda.hhs.gov

Howard Young, younghow@mail.nih.gov



Organized by
NIH/FDA Immunology Interest Group
NIH/FDA Cytokine Interest Group